ReviewInternational journal of nanomedicine2014
Near-infrared fluorescent probes in cancer imaging and therapy: an emerging field.
Review in International journal of nanomedicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed.
- Smart Immunomodulating Nanocomposites Enabling on-Demand Solid Tumor Treatment With Quasi-Real-Time Response Monitoring.Advanced healthcare materials · 2026Article
- Fluorescent Labeling Methods for Brain Structure Research.Molecules (Basel, Switzerland) · 2026Review
- Investigation of sentinel lymph nodes using SPECT/CT and perioperative gamma assay combined with immunohistochemistry in non-small cell lung cancer patients undergoing lung resection.Indian journal of thoracic and cardiovascular surgery · 2025Article
- Bimodal MRI/Fluorescence Nanoparticle Imaging Contrast Agent Targeting Prostate Cancer.Nanomaterials (Basel, Switzerland) · 2024Article
- New hybrid radio-fluorescent probes [Heliyon · 2023Article
- Hematoxylin Nuclear Stain Reports Oxidative Stress via Near-Infrared Emission.ACS chemical biology · 2023Article
- Tracking tumor heterogeneity and progression with near-infrared II fluorophores.Exploration (Beijing, China) · 2023Review
- Early cancer detection using the fluorescent Ashwagandha chitosan nanoparticles combined with near-infrared light diffusion characterization: in vitro study.Lasers in medical science · 2023Article
- Application of Nanoparticles in the Diagnosis of Gastrointestinal Diseases: A Complete Future Perspective.International journal of nanomedicine · 2023Review
- Indocyanine Green-based Glow Nanoparticles Probe for Cancer Imaging.Nanotheranostics · 2023Article
- Surfactant-chaperoned donor-acceptor-donor NIR-II dye strategy efficiently circumvents intermolecular aggregation to afford enhanced bioimaging contrast.Chemical science · 2022Article
- Design of an activatable NIR-II nanoprobe for theChemical science · 2022Article
- RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging.Molecular imaging and biology · 2022Article
- The Fluorescent Effect of Withania Somnifera Chitosan Nanocomposite as an Effective Contrast Agent for Cancer Theragnostic: Experimental Study in Vitro.Journal of fluorescence · 2022Article
- Ultrafast Collective Excited-State Dynamics of a Virus-Supported Fluorophore Antenna.The journal of physical chemistry letters · 2022Article
- Targeted Dual-Modal PET/SPECT-NIR Imaging: From Building Blocks and Construction Strategies to Applications.Cancers · 2022Review
- Structural Engineering of Fluorescent Self-Threaded Peptide Probes for Targeted Cell Imaging.Photochemistry and photobiology · 2022Article
- Side-chain modification of collagen-targeting peptide prevents dye aggregation for improved molecular imaging of arthritic joints.Journal of photochemistry and photobiology. A, Chemistry · 2022Article
- Towards Complete Tumor Resection: Novel Dual-Modality Probes for Improved Image-Guided Surgery of GRPR-Expressing Prostate Cancer.Pharmaceutics · 2022Article
- Visible-light and near-infrared fluorescence and surface-enhanced Raman scattering point-of-care sensing and bio-imaging: a review.Chemical Society reviews · 2022Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Near-infrared fluorescence (NIRF) imaging is an attractive modality for early cancer detection with high sensitivity and multi-detection capability. Due to convenient modification by conjugating with moieties of interests, NIRF probes are ideal candidates for cancer targeted imaging. Additionally, the combinatory application of NIRF imaging and other imaging modalities that can delineate anatomical structures extends fluorometric determination of biomedical information. Moreover, nanoparticles loaded with NIRF dyes and anticancer agents contribute to the synergistic management of cancer, which integrates the advantage of imaging and therapeutic functions to achieve the ultimate goal of simultaneous diagnosis and treatment. Appropriate probe design with targeting moieties can retain the original properties of NIRF and pharmacokinetics. In recent years, great efforts have been made to develop new NIRF probes with better photostability and strong fluorescence emission, leading to the discovery of numerous novel NIRF probes with fine photophysical properties. Some of these probes exhibit tumoricidal activities upon light radiation, which holds great promise in photothermal therapy, photodynamic therapy, and photoimmunotherapy. This review aims to provide a timely and concise update on emerging NIRF dyes and multifunctional agents. Their potential uses as agents for cancer specific imaging, lymph node mapping, and therapeutics are included. Recent advances of NIRF dyes in clinical use are also summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.